SDZ 249665

Drug Profile

SDZ 249665

Latest Information Update: 16 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Class Analgesics; Anti-inflammatories; Antiallergics
  • Mechanism of Action TRPV cation channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain; Rhinitis

Most Recent Events

  • 16 Jul 2010 Discontinued - Preclinical for Rhinitis in USA (SC)
  • 16 Jul 2010 Discontinued - Preclinical for Pain in USA (SC)
  • 14 Mar 2001 A study has been added to the Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top